Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Server is busy please try again later.  Join our daily free Newsletter

MENAFN Press - 17/10/2012
No. of Ratings : 0
Add to Mixx!



Due to technical reasons, this story has been removed from our database.

About CytoDyn Inc
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. CytoDyn intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. CytoDyn recently completed a humanized antibody construct of Cytolin(R), filed a provisional patent for its use, and manufacturing discussions are underway. In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and CytoDyn please go to www.cytodyn.com.Forward-Looking StatementsThis press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

 






  MENA News Headlines
 Sep 1 2014 - China to become GCC's biggest oil importerMENAFN
(MENAFN) China is set to depend heavily on the capacity of the Gulf Cooperation Council (GCC) to provide a stable flow of oil for the next ten years, Saudi Gazette reported.The deal earlier announced ...

 Sep 1 2014 - Kazakhstan to boost bilateral ties with OmanMENAFN
(MENAFN) Kazakhstan expressed its aims to boost bilateral relations with Oman with increased diplomatic visits and trade relations, Oman Observer reported.The Sultanate has contributed to ...

 Sep 1 2014 - 'City of Light' could recapture an intellectual leadership roleArab News
(MENAFN - Arab News) The holy city of Madinah has found a special place in World Economic Forum's report of the global agenda council on competitiveness.The report titled 'The Competitiveness of ...

 Sep 1 2014 - Final agreement for USD2b Omagine project near signingMENAFN
(MENAFN) A final agreement regarding the establishment of the Omagine real estate, tourism and entertainment project, which would cost USD2 billion and planned to be near Muscat International ...

 Sep 1 2014 - Global PTFE Market to Reach USD 6,440.0 Million by 2020MENAFN Press
(MENAFN Press) Global PTFE sales were estimated at USD 3,465.0 million in 2012, and are expected to reach USD 6,440.0 million by 2020, growing at a CAGR of 8.1% from 2013 to 2020, according to new ...

 Sep 1 2014 - Dubai set to stage Gary Barlow show in OctoberKhaleej Times
(MENAFN - Khaleej Times) Why the news of one pop concert in Dubai has wider (and happier) implications according to Adam Zacharias And so it begins.Earlier this week on my drive to work I heard on ...

 Sep 1 2014 - UAE- I always turned up with a couple of tapes: DJ NazKhaleej Times
(MENAFN - Khaleej Times) DJ Naz resident spinner at Toro Toro in Grosvenor House Dubai tells us about his musical beginnings and why hed like to follow in the footsteps of Ibn Battuta DJ style: ...

 Sep 1 2014 - UAE- Western Sydney Wanderers to feature in Al Jaziras IPIC CupKhaleej Times
(MENAFN - Khaleej Times) Western Sydney Wanderers who saw the back of last years champions Guangzhou Evergrande are set to touchdown in Dubai on Sunday.Ammar Bashir and Ali Al Nuaimi addressing the ...

 Sep 1 2014 - Emirati dies as car turns turtle on Malaiha road in SharjahKhaleej Times
(MENAFN - Khaleej Times) The victim was driving at the maximum speed while he lost control over the vehicle and hit a pole causing the car to flip over several times.A 23-year-old Emirati died and ...

 Sep 1 2014 - UAE- More patrols to be deployed near Fujairah schoolsKhaleej Times
(MENAFN - Khaleej Times) The Traffic and Patrols Department of the Fujairah Police has chalked out a plan to control traffic at the start of the new academic year.It will deploy 22 more patrols ...

more...


 






Google

Click to Apply

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help